Introduction {#S0001}
============

Host immunity could recognize and clear non-self immunogenic materials. Theoretically, neoantigens or tumor-associated antigens generated during oncogenesis could initiate anti-cancer immune attack. The robust anti-cancer immune response is usually described as cancer-immunity cycle model.[@CIT0001] Firstly, cancer cells-derived neoantigens or tumor-associated antigens are captured by dendritic cells (DCs). After antigen processing, DCs present cancer antigens with major histocompatibility complex (MHC) molecules to naïve T cells in peripheral lymphoid organs. Following the priming and activation, T cells could specifically recognize cancer antigens. Then, primed T cells traffic and infiltrate into tumor beds. Tumor-infiltrating lymphocytes (TILs) could directly eliminate tumor cells which further release more tumor antigens and upregulate the magnitude of anti-cancer immune response.[@CIT0001] However, this series of stepwise procedures tend to be interrupted by several factors such as downregulated MHC on tumor cells,[@CIT0002] immune editing,[@CIT0003] as well as increased immune checkpoints.[@CIT0004],[@CIT0005] As a result, malignant cells escape from immune attack and eventually develop into visible tumor mass.

Cancer immunotherapy is aiming to launch a self-sustaining cancer-immunity cycle which could self-amplify and self-propagate with minimized treatment-related auto-inflammation.[@CIT0006] Immune checkpoints such as programmed death 1 (PD-1),[@CIT0007] cytotoxic T lymphocyte antigen 4 (CTLA-4),[@CIT0008] lymphocyte activation gene 3 (LAG-3),[@CIT0009] as well as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3)[@CIT0010] are vital factors maintaining pro-tumor immune microenvironment, which are also regarded as ideal targets for cancer immunotherapy. However, anti-cancer immune response is a cyclic and stepwise process.[@CIT0011] The actual effect of anti-cancer immune elimination is determined by upstream immune editing (depletion of cancer cell sub-clones with T cell targets), downstream immunosuppressive tumor microenvironment including antigenic modulation and immune inhibitory cytokines especially transforming growth factor-beta (TGF-β) in tumor beds.[@CIT0012]--[@CIT0014] It is generally believed that the upregulated immune checkpoints on cancer cells are rate-limiting steps in cancer-immunity cycle.[@CIT0001],[@CIT0015] Nevertheless, the frequent ICIs resistance indicate that PD-1- or CTLA-4-targeted monotherapy could not completely counteract immunosuppression in the tumor microenvironment.[@CIT0016] A comprehensive framework containing multiple factors would be meaningful to remove adverse factors and amplify the whole anti-cancer immunity.[@CIT0017]

TGF-β is a versatile molecule which could bi-directionally regulate the initiation and progression of cancer.[@CIT0018]--[@CIT0020] Besides, TGF-β has a multifaceted influence on tumor immune microenvironment.[@CIT0021] Increasing evidence suggests that the excessive secretion of TGF-β in tumor closely relates to increased pro-tumor immune elements, restrained tumor-killing effect of TIL, as well as limited infiltration of immune effector cells.[@CIT0022]--[@CIT0024] TGF-β might be an evaluable target for cancer treatment and the dual-blockade of TGF-β/immune checkpoints would have a synergistic effect.

Immune Checkpoints In Tumor Microenvironment {#S0002}
============================================

T cell activation is a complex process containing two signals.[@CIT0025] The first activation signal is the specific binding of antigenic peptide-MHC complex on antigen presentation cell (APC) and T cell receptor (TCR) on naïve T cell.[@CIT0025] The second activation signal is also known as co-stimulatory signal which refers to the interaction between co-stimulatory molecules on APC and corresponding receptors on T cell.[@CIT0026] Simultaneous stimulations from first and second signals are the prerequisite of optimal T cell activation. In the absence of co-stimulatory, T cells are prone to be unresponsive to antigenic materials (anergic T cells).[@CIT0026] Besides, some negative co-stimulatory (also termed as co-inhibitory) signals participate in T cell activation as well. Under the physiology condition, co-inhibitory signals maintain peripheral tolerance and prevent anti-immune diseases via counterbalancing co-stimulatory signals.[@CIT0027],[@CIT0028] In tumor immune microenvironment, upregulated immune checkpoints blunt effector T cells and protect cancer cells from immune killing.[@CIT0029] Among all immune checkpoint pathways, PD-1/PD-L1 and CTLA-4/B7 (CD80/CD86) pathways are most well-studied. Multiple agents targeting PD-1, PD-L1, and CTLA-4 have been applied in clinic.[@CIT0030]--[@CIT0032]

PD-1-PD-L1 Signaling Pathway {#S0002-S2001}
----------------------------

PD-1 molecule consists of an extracellular IgV-like domain, a transmembrane domain, and an intracellular tail. The cytoplasmic tail of PD-1 contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immunoreceptor tyrosine-based switch motif (ITSM) which are the core structures for immune inhibitory function.[@CIT0033] PD-1 is widely expressed on multiple immune cells such as activated T cells, DCs, and natural killer cells (NKs).[@CIT0034]--[@CIT0036] The expression pattern of PD-L1 is different from PD-1. PD-L1 is constitutively expressed on immune cells including B cells, T cells, macrophages, DCs, and mesenchymal stem cells.[@CIT0037] Besides, the expression of PD-L1 could be transiently induced by a panel of cytokines especially interferon-gamma (IFN-γ).[@CIT0038],[@CIT0039] Apart from immune cells, a broad range of non-immune cells express PD-L1 as well.[@CIT0035] The upregulation of PD-L1 in tumor cells could be attributed to two factors. Firstly, some oncogenic pathways contribute to PD-L1 overexpression.[@CIT0040] Moreover, locally pre-existed inflammation leads to PD-L1 upregulation as a feedback termed as adaptive immune resistance.[@CIT0041]

PD-1 molecule could transduce the signal of PD-L1 when it is cross-linked with TCR. After the stimulation from TCR, the binding of PD-1 and PD-L1 activates this immune inhibitory pathway.[@CIT0042] The tyrosine residues of ITIM and ITSM are phosphorylated and recruit SHP1/2, which could counteract the TCR/CD3- or CD28-mediated phosphorylation.[@CIT0043] PD-1/PD-L1 signaling not only blocks TCR/CD3 pathway by dephosphorylating the core components of TCR downstream signaling such as Zap-70 and Lck but also inhibits PI3K-Akt and Ras-MEK-ERK pathways in T cells.[@CIT0044] The suppressed PI3K and MAPK pathways result in reduced glycolysis/amino acid metabolism and increased fatty acid oxidation. These metabolic changes of T cells propel the differentiation of T cells towards regulatory T cells (Tregs) and exhausted T cells but hamper the differentiation towards effector T cells and memory T cells.[@CIT0042] Besides T cell differentiation, PD-1 signaling could interrupt cell cycle process of T cells via inhibiting PI3K and MAPK pathways.[@CIT0042]

CTLA-4-B7 Signaling Pathway {#S0002-S2002}
---------------------------

Similarly to PD-1, CTLA-4 molecule contains an extracellular IgV-like domain, a transmembrane domain, and an intracellular tail as well.[@CIT0045] CTLA-4 is upregulated on activated T cells but rarely expressed on naïve T cells.[@CIT0046] Moreover, CTLA-4 is constitutively expressed on Tregs.[@CIT0047] Due to the similar molecular structure as well as higher affinity and avidity, CTLA-4 could competitively antagonize the binding between CD28 and B7.[@CIT0048] CTLA-4 inhibits T cell activation by multiple manners. Firstly, CTLA-4 could recruit phosphatases such as PP2A to reverse TCR/CD3 mediated phosphorylation of downstream proteins.[@CIT0049] Secondly, CTLA-4 downregulates the transcription of IL-2 which is the core cytokine for T cells activation and proliferation.[@CIT0049] Besides, CTLA-4 induces the abundance of B7 molecules on T cells by transendocytosis.[@CIT0047] Moreover, CTLA-4-B7 signaling pathway could induce the generation of several immune inhibitory components such as indoleamine-2, 3-dioxygenase (IDO) and TGF-β.[@CIT0050],[@CIT0051]

TGF-β Signaling Pathway And Cancer {#S0003}
==================================

Multiple cancers possess a TGF-β-enriched tumor microenvironment. Numerous components of tumor microenvironment including cancer cells, fibroblasts, macrophages, and platelets could secret TGF-β.[@CIT0052]

The Structure Of TGF-β {#S0003-S2001}
----------------------

The TGF-β family contains three members: TGF-β1, β2, and β3. All of the three cytokines are synthesized as precursors consisting of a signal peptide, a latency-associated peptide (LAP), a C-terminal fragment.[@CIT0053] Under the guidance of signal peptide, the TGF-β precursor is translocated to endoplasmic reticulum which is further assembled to a dimer by inter-chain disulfide bonds.[@CIT0054] After furin-mediated cleavage, the disulfide-linked C-terminal fragment is non-covalently associated with the disulfide-linked N-terminal LAP, which eventually form the small latent complex.[@CIT0054] The LAP domain folds around C-terminal fragment (mature TGF-β), blocking access of TGF-β to corresponding receptor.[@CIT0054] The active TGF-β homodimer is released from small latent complex by (1) extracellular protease cleavage; (2) in the assistance of latent TGF-β binding protein, separating active TGF-β by cell contraction-derived and integrin-mediated tension; (3) with the help of GARP on the cells such as Tregs or macrophages, releasing active TGF-β by cell contraction-derived and integrin-mediated tension.[@CIT0052],[@CIT0055] All the three TGF-β isoforms are highly homologous (71--79% sequence identity in C-terminal fragment TGF-β regions) and have the similar functions in vitro.[@CIT0054] In vivo studies showed that the predominantly immunity-related isoform was TGF-β1 and TGF-β1 deficiency led to embryonic lethal or severe multi-organ inflammation.[@CIT0056]

TGF-β Signaling Pathway {#S0003-S2002}
-----------------------

TGF-β signal is transduced by TGF-β receptor complex which consists of a TGF-βI receptor homodimer (TGF-βRI) and a TGF-βII receptor homodimer (TGF-βRII).[@CIT0057] Firstly, extracellular TGF-β binds to TGF-βRII homodimer which further complex with TGF-βRI homodimer.[@CIT0057] Following TGF-β engagement, TGF-βRII homodimer phosphorylates the intracellular domain of TGF-βRI.[@CIT0057] Notably, the transduction of TGF-β2 is usually with the assistance of co-receptor β-glycan (also termed as TGF-βRIII).[@CIT0057] The engagement of TGF-β receptor complex recruits receptor Smad (R-Smad) molecules Smad2 and 3 to the intracellular domain of TGF-βRI.[@CIT0058] Subsequently, Smad2 and 3 are phosphorylated which then form a trimeric complex with Smad4.[@CIT0058] The trimeric Smad complex could translocate to nuclear and regulate gene expression.[@CIT0058] Besides, phosphorylated Smad 2 and 3 could also form a trimeric complex with TIF1γ to regulate the expression of targeting genes.[@CIT0054] Moreover, it was reported that some other members of Smad family including Smad 1 and 5 might participate in TGF-β signaling pathway in partial cells such as Th17 cells.[@CIT0059] Apart from classic Smad pathway, TGF-β signal could also be transduced by some Smad-independent pathways such as PI3K, MAPK, and Rho GTPase pathways.[@CIT0060]--[@CIT0062] It has been well-established that the exact downstream signaling pathway of TGF-β signal is context-dependent.[@CIT0054]

TGF-β Pathway And Cancer Progression {#S0003-S2003}
------------------------------------

The role of TGF-β pathway is bi-directional for cancer.[@CIT0020] For pre-malignant cells, TGF-β acts as a tumor suppressor via suppressing cell proliferation and promoting cell apoptosis.[@CIT0063] However, for advanced cancer, TGF-β promotes cancer metastasis and induces pro-tumor immune microenvironment.[@CIT0063] In the tumor microenvironment, by paracrine and autocrine ways, overexpressed TGF-β could regulate the functions of cancer cells and stromal cells.[@CIT0064] The increased TGF-β is contributed by cancer cells especially cancer stem cells, Tregs, Bregs, tumor-associated macrophages (TAMs), cancer-associated fibroblasts (CAFs), as well as myeloid-derived suppressor cells (MDSCs).[@CIT0064] Notably, Stanford et al found that in postpartum breast cancers, dying cancer cells could be engulfed by neighboring macrophages (the process is also known as efferocytosis) via receptor tyrosine kinase MerTK.[@CIT0065] As a result, this efferocytosis enhanced the transcription of multiple wound-healing cytokines including TGF-β.[@CIT0065] So far, the mechanism by which the production of TGF-β is increased in CAFs is not clear yet. Previous studies indicated multiple components in the tumor microenvironment such as bone marrow-derived mesenchymal stem cells participated in the transformation of normal fibroblasts to CAFs and enhanced the secretion of TGF-β of CAFs.[@CIT0066] Besides, some cancer-specific miRNA expression pattern elevated the TGF-β generation in CAFs as well. Tanaka et al reported that in esophageal cancers, increased extracellular miR-27 was an unfavorable predictive factor for prognosis. After miR-27a/b transfection, normal fibroblasts exhibited more CAFs-associated markers including increased expression of α-smooth muscle actin and TGF-β.[@CIT0067]

As a growth-inhibitory cytokine, TGF-β could effectively suppress cell proliferation by increasing the activity of cyclin-dependent kinase inhibitors such as p15INK4, p21CIP1, and p27KIP1.[@CIT0068]--[@CIT0070] Simultaneously, TGF-β could downregulate the expression of Myc.[@CIT0071] Besides, TGF-β inhibits tumorigenic inflammation and maintains immune homeostasis.[@CIT0063] Therefore, TGF-β exhibits tumor-suppressing function during the early stage of carcinogenesis.[@CIT0052] However, persistent TGF-β exposure introduces selective pressure and a subset of cancer cells could overcome TGF-β-related tumor-suppressing effect and eventually develop to advanced tumor.[@CIT0063] Actually, the transformation of TGF-β from cancer promotor to cancer suppressor occurs by two approaches.[@CIT0063] Firstly, partial cancer cells acquire mutations in TGF-β signaling pathway and abrogate TGF-β-mediated tumor-suppressing effect.[@CIT0052] In the same time, TGF-β signaling in stromal cells promotes cancer progression by inhibiting immune surveillance and promoting the secretion of some carcinogenic cytokines such as IL-11.[@CIT0063] Besides, oncogenes or tumor suppressors interact with TGF-β signaling and switch TGF-β function.[@CIT0072] For some cancer cells with intact TGF-β signaling pathway, some oncogenic pathways could counteract the pro-apoptosis effect of TGF-β.[@CIT0052] As a result, cancer cells undergo non-lethal epithelial--mesenchymal transition (EMT) and obtain the increased capabilities of migration and distant colonization.[@CIT0052]

Notably, overexpressed TGF-β in the tumor microenvironment is highly related with hypoxia. Stephen et al found that breathing supplementary oxygen could effectively relieve regional hypoxia and decrease TGF-β abundance in tumors.[@CIT0073] This treatment using supplementary oxygen convert immunosuppressive and TGF-β-enriched tumor microenvironment to normal microenvironment, which is a promising adjuvant strategy to restore robust anti-cancer immune response.[@CIT0074]

The Effect Of TGF-β Signaling Pathway On Immunity {#S0004}
=================================================

TGF-β signaling pathway has a substantial influence on various immune cells which not only participates in immune cell differentiation but also regulates the activity of immune components ([Figure 1](#F0001){ref-type="fig"}).[@CIT0075] Generally, TGF-β acts as an inflammation-inhibitory factor.Figure 1TGF-β signaling pathway and its role in tumor immune microenvironment. TGF-β signal is transduced by TGF-β receptor complex which consists of TGF-βI receptors and TGF-βII receptors (TGF-βRI and TGF-βRII). Firstly, extracellular TGF-β binds to TGF-βRII homodimer which further complex with TGF-βRI homodimer. Following TGF-β engagement, TGF-βRII homodimer phosphorylates the intracellular domain of TGF-βRI. The engagement of TGF-β receptor complex recruits receptor Smad (R-Smad) molecules Smad2 and 3 to the intracellular domain of TGF-βRI. Subsequently, Smad2 and 3 are phosphorylated which then form a trimeric complex with Smad4. The trimeric Smad complex could translocate to nuclear and regulate gene expression. Besides, phosphorylated Smad2 and 3 could also form a trimeric complex with TIF1γ to regulate the expression of targeting genes. Apart from classic Smad pathway, TGF-β signal could also be transduced by some Smad-independent pathways such as PI3K, MAPK, and Rho GTPase pathways. TGF-β signaling pathway has a substantial influence on various immune cells including downregulating the cytotoxicity of effector T cells and NKs, promoting the apoptosis of effector T cells, inducing the differentiation towards Tregs, hampering the antigens presentation of DCs.**Abbreviations:** NK, natural killer cell; CAF, cancer-associated fibroblast; MHC, major histocompatibility complex; IDO, indoleamine-2, 3-dioxygenase; Id1, inhibitor of differentiation 1; Treg, regulatory T cell.

Th1 Cell {#S0004-S2001}
--------

Th1 cell is a vital player in anti-cancer immunity and the differentiation of Th1 cells needs APC-derived cytokine IL-12.[@CIT0076] IL-12 could induce Th1 cell to generate abundant IFN-γ and the secretion of IFN-γ could be self-propagated as a positive feedback loop.[@CIT0077] Besides, IL-12 upregulates the expression of key transcription factor T-bet which is the other determinant for Th1 cell differentiation.[@CIT0076] TGF-β could effectively hamper Th1 cell differentiation. Firstly, TGF-β reduces the expression of the receptor of IL-12 on Th0 cells and downregulates the sensitivity of Th0 cells to IL-12.[@CIT0078] Secondly, TGF-β downregulates the level of T-bet in Th1 cells.[@CIT0079] Thirdly, TGF-β inhibits the production of IL-12 of NK.[@CIT0080] Although most previous studies showed that TGF-β suppressed the Th1 differentiation, some studies also indicated that TGF-β could also induce Th1 cell differentiation in some certain background such as in the presence of IFN-γ or IL-4.[@CIT0081] However, the significance of TGF-β-mediated Th1 cell differentiation under certain condition needs further exploration.

CD8^+^ T Cell {#S0004-S2002}
-------------

In addition to Th1 cell differentiation, TGF-β could inhibit T cell proliferation by Smad signaling pathway. Previous studies showed TGF-β suppressed CD4^+^ and CD8^+^ T cell proliferation via downregulating the transcription of IL-2 and c-Myc, as well as upregulating p21Cip1 and p27Kip1.[@CIT0082]--[@CIT0084] Besides, TGF-β directly inhibits the cytotoxic activity of CD8^+^ T cells.[@CIT0085] The undermined lytic function is related to TGF-β-Smad signaling-mediated downregulation of granzyme A, B, perforin, Fas ligand, and IFN-γ.[@CIT0014]

Treg {#S0004-S2003}
----

CD4^+^ CD25^+^ Foxp3^+^ Treg cell is a vital subpopulation of T cells which maintains immune homeostasis and participates in cancer immune evasion.[@CIT0086] TGF-β could suppress immune response by regulating Treg cells. The results of mouse experiments indicated that mice lacking TGF-β1 or harboring TGF-βRII deficiency in T cells had decreased Foxp3^+^ Treg cells in peripheral blood.[@CIT0087],[@CIT0088] In the presence of IL-2, TGF-β promotes the differentiation of naïve T cells towards Treg cells.[@CIT0089] Upon TCR engagement, Smad3 interacts with the enhancer region of Foxp3 (CNS1).[@CIT0090] Besides, Smad3 could upregulate Foxp3 transcription by forming enhanceosome complex with NFATc2 and CREB.[@CIT0091] The level of Foxp3^+^ Treg cells is remarkably reduced in Smad3 knockout mice.[@CIT0092] Although Smad2 could not directly interact with CNS1, T cells lacking Smad2 showed reduced Foxp3 expression.[@CIT0093] The effect of Smad2 on Foxp3 level was proposed to depend on the interaction between Smad2 and Smad3.[@CIT0054] Apart from Smad pathway, TGF-β could indirectly promote Foxp3 expression by counteracting Foxp3 transcription inhibitory factor such as Gfi-1.[@CIT0094]

DC {#S0004-S2004}
--

DC is the key component of cancer-immunity cycle which captures antigenic materials from cancer cells and activates cancer-specific lymphocytes. TGF-β suppresses the antigen presentation of DC by decreasing the expression of MHCII.[@CIT0095] Hypersecretion of TGF-β in tumor microenvironment propels the transformation of DC towards immature myeloid cell phenotype which exhibits potent immune inhibitory effect.[@CIT0096] This transformation is attributed to multiple reasons. Firstly, TGF-β could upregulate the level of inhibitor of differentiation 1 which inhibits the differentiation of DC and proliferation of CD8^+^ T cells.[@CIT0096] Moreover, TGF-β promotes the formation of regulatory phenotype DC by inducing IDO in plasmacytoid DC and chemokine (C-C motif) ligand 22 (CCL22) chemokine in myeloid DC.[@CIT0097],[@CIT0098]

Macrophage {#S0004-S2005}
----------

TAM is the important source of TGF-β in tumor microenvironment.[@CIT0099] Besides, TAM activates TGF-β from its precursor via extracellular integrin αvβ8 and matrix metalloproteinase 14.[@CIT0099] It has been reported that TGF-β could inhibit NF-κB signaling-mediated inflammation response by promoting the degeneration of MYD88.[@CIT0100] Besides, TGF-β inhibits the inflammation phenotype macrophages by the interaction between inhibitory molecule Smad7 and TNF signaling pathway, which might contribute to immunosuppressive tumor microenvironment.[@CIT0052]

NK {#S0004-S2006}
--

NKs could rapidly respond to a broad range of pathogen challenges, detect, and kill malignant cells. It is notable that NKs kill cancer cells independent on priming and activation processes. Besides, NKs enhance anti-cancer effect of adaptive immunity by secreting cytokines such as IFN-γ and tumor necrosis factor-α (TNF-α).[@CIT0101] TGF-β substantially suppresses the functions of NKs by blocking the expression of IFN-γ.[@CIT0080] Moreover, TGF-β downregulates the levels of NKG2D and NKp30 on NKs, which mediates the recognition of stressed cells.[@CIT0102]

CAF {#S0004-S2007}
---

The ratio of CAF is usually increased in the microenvironment of advanced cancers. CAFs generate multiple materials including fibroblast activation protein, α-smooth muscle actin, extracellular matrix proteins (e.g., type I collagen and fibronectin), and various cytokines.[@CIT0103] Actually, CAF is the main producer of TGF-β for multiple cancer types. Previous study showed that increased TGF-β secreted by CAF and other cells suppressed anti-tumor immune response.[@CIT0104]

Besides, CAF could be activated by TGF-β as well. The transcriptome analysis of patients undergoing ICI treatment showed that TGF-β-activated CAF gene program was highly correlated with ICI resistance.[@CIT0022] However, anti-TGF-β treatment could effectively convert T cell exclusion and enhance the efficacy of ICIs.[@CIT0022] The exact mechanisms by which TGF-β-activated CAFs lead to cancer immune escape are attributed to three reasons. Apart from the contribution of CAF to the upregulation of TGF-β, TGF-β propels the morphological alterations in CAFs which is helpful to the release of active TGF-β from latent complex.[@CIT0052] Moreover, activated TGF-β signaling pathway hampers the infiltration of T cells by remodeling the matrix architecture in the tumor stroma.[@CIT0052],[@CIT0105]

Dual Blockade Of TGF-β And Immune Checkpoint {#S0005}
============================================

In tumor microenvironment, cancer cells usually hijack multiple immune inhibitory pathways to escape immune surveillance. Dysregulated TGF-β signaling pathway impaired multiple processes in anti-cancer immune response including antigen presentation, T cell infiltration, and tumor-killing activity. Therefore, ICI monotherapy might fail to restore robust anti-cancer immune response ([Figure 2](#F0002){ref-type="fig"}). Feun et al reported the results of NCT02658019 and found the baseline plasma TGF-β levels were significantly correlated to the poor outcomes of pembrolizumab-treated advanced hepatocellular carcinoma patients.[@CIT0106] Given the potentially synergistic effect of TGF-β pathway and immune checkpoint in inducing immune tolerance, a series of studies were conducted to explore the efficacy of combination strategy of TGF-β inhibitor and ICI for cancer treatment ([Table 1](#T0001){ref-type="table"}).[@CIT0107]Table 1Clinical Trials Of Dual Blockade Of TGF-β And Immune CheckpointStudyCombination StrategyCancer TypePhaseStatusNCT03821935ABBV-151 and ABBV-181Advanced solid tumors cancerIRecruitingNCT03631706M7824NSCLCIIRecruitingNCT03840915M7824Carcinoma, NSCLCI/IIRecruitingNCT03427411M7824HPV associated malignanciesIIRecruitingNCT03840902M7824NSCLCIIRecruitingNCT03833661M7824Biliary tract cancerIIRecruitingNCT03579472M7824Triple negative breast cancerIRecruitingNCT03451773M7824Adenocarcinoma of the pancreasI/IIRecruitingNCT03436563M7824Colorectal cancer or advanced solid tumors with microsatellite instabilityI/IIRecruitingNCT02947165NIS793 and PDR001Advanced malignanciesIRecruitingNCT03192345SAR439459 and CemiplimabAdvanced solid tumorsIRecruitingNCT03724851Vactosertib and PembrolizumabColorectal or gastric cancerI/IINot yet recruitingNCT03732274Vactosertib and DurvalumabNSCLCI/IINot yet recruitingNCT02423343Galunisertib and NivolumabAdvanced refractory solid tumors and in recurrent or refractory nsclc, or hepatocellular carcinomaI/IIActive, not recruitingNCT02734160Galunisertib and DurvalumabPancreatic cancerIActive, not recruiting[^2] Figure 2The synergistic effect of TGF-β pathway and immune checkpoint in inducing immune tolerance. Dysregulated TGF-β signaling pathway impaired multiple processes in anti-cancer immune response including antigen presentation, T cell infiltration, and tumor-killing activity. Hyperactive TGF-β signaling together with increased PD-1/PD-L1 signal axis undermine anti-cancer immune response.

TGF-β Inhibitor Plus ICI {#S0005-S2001}
------------------------

By establishing human microsatellite stable-like colorectal cancers in mice, Tauriello et al found that ICI monotherapy could not effectively eliminate cancer cells.[@CIT0104] However, additional TGF-β blockade remarkably enhanced the anti-cancer effect of ICI.[@CIT0104] The further exploration indicated that TGF-β could induce immune suppression by promoting the formation of T cell-exclusion phenotype tumors which were prone too resistant to ICI treatment.[@CIT0104] Simultaneously, Mariathasan et al noticed the similar phenomenon in patients with metastatic urothelial cancer.[@CIT0022] For metastatic urothelial cancer patients receiving atezolizumab treatment, the treatment response was highly related with the activity of TGF-β signaling pathway in fibroblasts, especially in patients with abundant CD8^+^ T cells enriched in peritumoral stroma rather than tumor center (immune excluded phenotype).[@CIT0022] Researchers recapitulated the immune-excluded phenotype tumors with EMT6 mouse mammary and MC38 mouse colon carcinoma model. Although neither following atezolizumab nor TGF-β blockade could reduce tumor burden, the combination therapy of atezolizumab and TGF-β blockade potently eradicated cancer cells in the two models.[@CIT0022] Further investigation suggested that the synergistic effect of dual-blockade was attributed to enhanced T cell infiltration into tumor center and anti-tumor immune response.[@CIT0022]

In addition to increased T cell infiltration, Terabe et al found that blocking TGF-β1 and TGF-β2 significantly elevated cancer vaccine-induced Th1-type immune response, upregulated IFN-γ production, and increased T-bet expression of tumor-infiltrating CD8^+^ T cells.[@CIT0108] Besides, TGF-β blockade could enhance the treatment effect of cancer vaccine and anti-PD-1 antibody in mice models.[@CIT0108] Similarly, Chen et al found that TGF-β secreted by MDSCs was highly associated with PD-1/PD-L1 inhibitor resistance by inducing PD-1 upregulation on CD8^+^ T cells in tumor bed.[@CIT0109] TGF-β blockade significantly promoted the lytic function of tumor antigen-specific CD8^+^ T cells in vivo and in vitro.[@CIT0109]

Fusion Antibody Simultaneously Targeting TGF-β And Immune Checkpoint {#S0005-S2002}
--------------------------------------------------------------------

In 2018, Lan et al designed a bifunctional fusion protein (M7824) which consisted of a PD-L1 monoclonal antibody and the extracellular domains of human TGFβR-II.[@CIT0110],[@CIT0111] M7824 could simultaneously block cancer cell extrinsic and intrinsic immunosuppressive pathways.[@CIT0110] Under the guidance of PD-L1 monoclonal antibody moiety, M7824 could preciously locate into tumor microenvironment and further neutralize the abundant TGF-β. In vitro study showed that partial M7824 would be internalized after incubation with 293 cells ectopically expressing PD-L1.[@CIT0110] In vivo study M7824 exhibited potent tumor control effect superior to isotype control, trap control, as well as PD-L1 monoclonal antibody.[@CIT0110] Besides, M7824 treatment effectively prolonged survival time in mice bearing EMT6 or MC38 carcinomas.[@CIT0110] Subsequent investigation showed that M7824 elevated both quantity and immune ability of tumor-infiltrating lymphocytes such as CD8^+^ T cells, NKs, DCs, and macrophages.[@CIT0110] Later, Ravi et al reported another bifunctional fusion protein targeting CTLA-4 and TGFβR-II.[@CIT0112] This bifunctional fusion protein could inhibit the differentiation of Tregs and Th17 cells, and increase tumor-specific IFN-γ^+^ effector and memory cells.[@CIT0112] The anti-cancer effect of anti-CTLA4-TGFβR-II fusion protein was superior to CTLA-4 or PD-1 inhibitors.[@CIT0112]

Conclusion {#S0006}
==========

The biologic effects of TGF-β signaling pathway are highly context-dependent. In addition to the pleiotropic function as a tumor promoter or suppressor, TGF-β pathway could induce immune suppression and participate in immune homeostasis or immune evasion. For normal tissues especially for ones consistently exposure to antigenic materials, intact TGF-β pathway could decrease the risk of inflammation-related malignant transformation. However, for advanced tumor tissues, hyperactive TGF-β pathway undermines immune surveillance and promotes tumor immune escape. TGF-β pathway broadly inhibits multiple anti-cancer producers including T cell priming and activation, immunosuppressive lymphocyte differentiation, cytotoxic function of effectors. Thus, additional TGF-β blockade might effectively enhance the ICI therapy for TGF-β-enriched tumors. We believe that the dual blockade of TGF-β and immune checkpoint would be a promising strategy in clinical practice in the future.
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